1. Home
  2. JYNT vs CGEN Comparison

JYNT vs CGEN Comparison

Compare JYNT & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JYNT
  • CGEN
  • Stock Information
  • Founded
  • JYNT 2010
  • CGEN 1993
  • Country
  • JYNT United States
  • CGEN Israel
  • Employees
  • JYNT N/A
  • CGEN N/A
  • Industry
  • JYNT Multi-Sector Companies
  • CGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • JYNT Miscellaneous
  • CGEN Health Care
  • Exchange
  • JYNT Nasdaq
  • CGEN Nasdaq
  • Market Cap
  • JYNT 149.5M
  • CGEN 125.3M
  • IPO Year
  • JYNT 2014
  • CGEN 2000
  • Fundamental
  • Price
  • JYNT $7.80
  • CGEN $1.58
  • Analyst Decision
  • JYNT Strong Buy
  • CGEN
  • Analyst Count
  • JYNT 3
  • CGEN 0
  • Target Price
  • JYNT $16.33
  • CGEN N/A
  • AVG Volume (30 Days)
  • JYNT 79.8K
  • CGEN 522.7K
  • Earning Date
  • JYNT 11-06-2025
  • CGEN 11-10-2025
  • Dividend Yield
  • JYNT N/A
  • CGEN N/A
  • EPS Growth
  • JYNT N/A
  • CGEN N/A
  • EPS
  • JYNT N/A
  • CGEN N/A
  • Revenue
  • JYNT $54,176,002.00
  • CGEN $22,144,000.00
  • Revenue This Year
  • JYNT $7.70
  • CGEN N/A
  • Revenue Next Year
  • JYNT $10.24
  • CGEN $208.08
  • P/E Ratio
  • JYNT N/A
  • CGEN N/A
  • Revenue Growth
  • JYNT 263.87
  • CGEN N/A
  • 52 Week Low
  • JYNT $7.50
  • CGEN $1.13
  • 52 Week High
  • JYNT $13.47
  • CGEN $2.66
  • Technical
  • Relative Strength Index (RSI)
  • JYNT 33.30
  • CGEN 44.43
  • Support Level
  • JYNT $7.69
  • CGEN $1.61
  • Resistance Level
  • JYNT $8.62
  • CGEN $1.80
  • Average True Range (ATR)
  • JYNT 0.31
  • CGEN 0.11
  • MACD
  • JYNT 0.03
  • CGEN -0.03
  • Stochastic Oscillator
  • JYNT 18.33
  • CGEN 19.35

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: